State finalists for Student Excellence Awards announced
18 October, 2012 by AusBiotechThe state finalists of the 2012 AusBiotech/GSK Student Excellence Awards have been announced. Sixteen promising research students competed for the chance to represent their state, and the six state finalists will now compete at the AusBiotech national conference to win a $7,000 travel grant.
Bionomics presenting early Alpha 7 data
17 October, 2012 by Dylan Bushell-EmblingBionomics (ASX:BNO) is presenting details of its its Alpha 7 program targeting Alzheimers and other neurodegenerative conditions at Neuroscience 2012, as it embarks on the hunt for a licensing deal.
STA licenses treatment for cachexia-anorexia
17 October, 2012 by Dylan Bushell-EmblingSpecialised Therapeutics Australia (STA) has negotiated commercialisation rights for a new drug to treat cachexia-anorexia, a serious condition linked with advanced cancers.
CSL to conduct another $900m buyback
17 October, 2012 by Dylan Bushell-EmblingCSL (ASX:CSL) has announced another up to $900 million share buyback, and has affirmed its guidance for FY13.
Clinuvel data show SCENESSE accelerates repigmentation
16 October, 2012 by Dylan Bushell-EmblingThe first published data from Clinuvel's (ASX:CUV) trial of SCENESSE in patients with skin condition vitiligo indicate that the treatment can help accelerate repigmentation of the skin.
Biotron hepatitis treatment looks promising
16 October, 2012 by Dylan Bushell-EmblingData from a trial of Biotron's (ASX:BIT) novel hepatitis C (HCV) treatment candidate shows that all patients treated with the highest dose had undetectable levels of the virus at 48-week follow up.
Feds announce another review on patents
16 October, 2012 by AusBiotechThe Federal Government has announced the commission of an expert panel to review the “appropriateness of the extension arrangements for pharmaceutical patents.” This review is part of a broad range of measures the Government is undertaking to scrutinise the Australian patent system.
Promising results from Prima BioMed ovarian cancer trial
15 October, 2012 by Dylan Bushell-EmblingPrima BioMed (ASX:PRR) has reported promising interim results from a phase II trial of CVac, its prospective ovarian cancer vaccine.
Nanosonics wins NSW Export Award
12 October, 2012 by Dylan Bushell-EmblingNanosonics (ASX:NAN) has been entered as a finalist in the Australian Export Awards, after winning recognition at yesterday's Premier's NSW Export Awards.
Benitec to buy Tacere and its new hepatitis C treatment drug
11 October, 2012 by Dylan Bushell-EmblingBenitec Biopharma (ASX:BLT) will acquire Tacere Therapeutics, which has a phase I/II ready hepatitis C treatment candidate developed using Benitec's ddRNAi technology.
Bionomics chairman to step down
11 October, 2012 by Dylan Bushell-EmblingBionomics (ASX:BNO) has announced that chairman Chris Fullerton will leave the company at the end of the year, and will be replaced by Graeme Kaufman.
AusBiotech Annual Report 2012 details year of significance
11 October, 2012 by AusBiotechThe AusBiotech Annual Report 2012, released this week, details another significant period for AusBiotech and for the Australian biotechnology industry.
QRxPharma scores Canadian licensing deal for MoxDuo
10 October, 2012 by Dylan Bushell-EmblingQRxPharma (ASX:QRX) has secured a potentially lucrative licensing deal covering the Canadian market for its pain relief drug, MoxDuo IR, which is currently awaiting marketing approval in Canada and the US.
AusBiotech welcomes McKeon Review focus on translation
09 October, 2012 by AusBiotechThe McKean Review has reported recently, providing a consultation paper for comment until the end of October.
Vaxxas partners with Merck on Nanopatch needle-free vaccine patch
09 October, 2012 by Dylan Bushell-EmblingStart-up Vaxxas has picked up its first major pre-licensing and evaluation deal for Nanopatch, the needle-free vaccine technology developed at the AIBN, collaborating with Merck.
